Promising Biotech Stocks To Research – May 1st

Thermo Fisher Scientific, AbbVie, Danaher, ICON Public, SpringWorks Therapeutics, Vertex Pharmaceuticals, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Error: Response status code does not indicate success: 429 (Too Many Requests). These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

TMO traded down $6.40 on Thursday, hitting $422.60. 889,124 shares of the company traded hands, compared to its average volume of 1,755,143. The company has a 50 day moving average of $480.79 and a 200-day moving average of $524.13. The stock has a market capitalization of $159.53 billion, a PE ratio of 25.65, a PEG ratio of 2.99 and a beta of 0.86. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific has a 12-month low of $409.85 and a 12-month high of $627.88.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of NYSE:ABBV traded down $0.71 during midday trading on Thursday, reaching $194.40. The company’s stock had a trading volume of 1,892,248 shares, compared to its average volume of 6,060,484. AbbVie has a 1 year low of $153.58 and a 1 year high of $218.66. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94. The business has a 50 day moving average price of $196.46 and a 200 day moving average price of $187.22. The firm has a market cap of $343.88 billion, a price-to-earnings ratio of 81.20, a price-to-earnings-growth ratio of 1.62 and a beta of 0.55.

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Shares of NYSE DHR traded down $2.27 on Thursday, hitting $197.06. The company had a trading volume of 1,720,178 shares, compared to its average volume of 3,353,698. The firm has a market capitalization of $141.03 billion, a P/E ratio of 37.40, a PEG ratio of 2.66 and a beta of 0.86. Danaher has a 12-month low of $171.00 and a 12-month high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The business has a 50 day moving average of $200.30 and a two-hundred day moving average of $223.12.

ICON Public (ICLR)

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

ICON Public stock traded down $7.46 during mid-day trading on Thursday, hitting $143.98. The company’s stock had a trading volume of 1,597,750 shares, compared to its average volume of 959,224. The company has a quick ratio of 1.34, a current ratio of 1.26 and a debt-to-equity ratio of 0.36. ICON Public has a twelve month low of $133.28 and a twelve month high of $347.72. The stock has a market capitalization of $11.63 billion, a P/E ratio of 15.14, a P/E/G ratio of 1.86 and a beta of 1.24. The stock’s fifty day moving average price is $167.20 and its two-hundred day moving average price is $198.21.

SpringWorks Therapeutics (SWTX)

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.

SWTX stock traded down $0.04 during mid-day trading on Thursday, hitting $46.27. The stock had a trading volume of 3,876,797 shares, compared to its average volume of 1,883,526. The stock has a market capitalization of $3.47 billion, a price-to-earnings ratio of -13.30 and a beta of 0.79. The company has a fifty day moving average of $45.49 and a 200 day moving average of $40.82. SpringWorks Therapeutics has a 1-year low of $28.21 and a 1-year high of $62.00.

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Shares of VRTX traded down $7.73 during trading hours on Thursday, reaching $501.77. 344,673 shares of the company traded hands, compared to its average volume of 1,335,691. The stock’s fifty day moving average is $491.24 and its 200 day moving average is $466.94. Vertex Pharmaceuticals has a 1-year low of $377.85 and a 1-year high of $519.88. The stock has a market cap of $129.00 billion, a P/E ratio of -228.22, a price-to-earnings-growth ratio of 2.11 and a beta of 0.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69.

Moderna (MRNA)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

MRNA stock traded down $1.95 during trading on Thursday, hitting $26.59. The company had a trading volume of 6,103,935 shares, compared to its average volume of 7,384,665. The firm has a 50-day moving average price of $29.77 and a 200-day moving average price of $38.02. The stock has a market cap of $10.28 billion, a price-to-earnings ratio of -2.87 and a beta of 2.23. Moderna has a 12 month low of $23.15 and a 12 month high of $170.47.